cMET Inhibitor Capmatinib Upgraded to Priority Review by FDA for NSCLC

by Dr. C.H. Weaver M.D. updated 2/2020

The U.S. Food and Drug Administration initially granted Breakthrough Therapy Designation to capmatinib (INC280) as a first-line treatment for patients with metastatic mesenchymal-epithelial transition (MET) exon14 skipping-mutated non-small cell lung cancer (NSCLC) and has now changed the designation to "priority review" based on the results of the GEOMETRY

MET is a cancer driving mutation (1,2) that is seen in approximately 3% to 4% of patients with NSCLC, (3) and is associated with a poor prognosis. (4,5) Capmatinib is a precision cancer medicine that has been shown to be a highly potent and selective MET inhibitor and has been granted Priority Review by the FDA based on positive primary results from the GEOMETRY mono-1 clinical study presented at the 2019 Annual Meeting of the American Society of Clinical Oncology. (6)

About Capmatinib (INC280)

Capmatinib is an oral medication that inhibits the proto-oncogene c-Met’s anticancer activity. c-Met is a protein that in humans is encoded by the MET gene. The c-Met protein possesses tyrosine kinase activity and plays a key role in cancer cell proliferation, survival, invasion, metastasis, and angiogenesis. Capmatinib selectively inhibits c-Met phosphorylation and disrupts c-Met signal transduction pathways leading to cell death in cancer cells over expressing the c-Met protein.

The GEOMETRY mono-1 clinical trial evaluated 97 adult patients with locally advanced or metastatic NSCLC with the MET exon-14 skipping mutation who were treated with capmatinib. Overall 68% of these patients responded to treatment for an average response duration of 11 months. Responses were also reported in 54% of patients with brain lesions.

The most common reported side effects associated with capmatinib include nausea, vomiting, fatigue, decreased appetite, and diarrhea.

Priority review for capmatinib will shorten the FDA review period on the manufacturer’s new drug application from the standard 10 months to 6 months.

Capmatinib-Iressa Combination

The combination of Iressa (gefitinib) and Capmatinib has also been evaluated and appears to be safe and effective for the treatment of epidermal growth factor receptor (EGFR)-mutated, MET factor-dysregulated NSCLC.

The EGFR is involved in cellular replication and growth, and a mutation within the EGFR can lead to the development and spread of cancer cells. Patients with NSCLC that has an EGFR mutation are treated with EGFR tyrosine kinase inhibitor drugs that block the effects of the mutated EGFR.

Iressa is one of several EGFR drugs that are used for the treatment of patients whose cancer express’s the most common type of EGFR mutations in NSCLC (exon 19 deletions or exon 21 L858R substitution gene mutations).

Researchers believe that combining EGFR and c-Met inhibition may lead to improved anti-cancer responses in NSCLC. To test this approach doctors performed a phase 1b/2 clinical trial in 161 patients with EGFR-mutated, MET-dysregulated NSCLC that had progressed during prior EGFR-tyrosine kinase inhibitor treatment. Patients were treated with the combination of Iressa, and capmatinib capsules at varying doses. The combination therapy was generally well tolerated and overall 47% of individuals responded to treatment and 73% were reported to have either responsive or stable disease.

The study results, published in the Journal of Clinical Oncology demonstrate that the combination of capmatinib and Iressa is feasible, rational and may be a promising treatment option for patients with EGFR-mutated, MET-dysregulated NSCLC. The continued development of capmatinib is occurring in clinical trials.(7)

References:

  1. Smyth EC, et al. Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors. Onco Targets Ther. 2014;7:1001-1014.
  2. Sadiq AA, Salgia R. MET as a possible target for non-small-cell lung cancer. J Clin Oncol 2013;31:1089-96.
  3. Salgia R. MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale. Mol Cancer Ther. 2017;16(4):555-565.
  4. Cappuzzo F, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 2009;27:1667-74.
  5. Tong JH, et al. MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis. Clin Cancer Res 2016;22:3048-56.
  6. [<a href="http://bit.ly/2L7L3ta]">http://bit.ly/2L7L3ta]</a>
  7. Wu YL, Zhang L, Kim DW, et al. Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor–dysregulated non–small-cell lung cancer. J Clin Oncol. 2018;36:3101-3109. doi: 10.1200/JCO.2018.77.7326
  8. Wolf J, et al. Abstract 9004. Presented at: ASCO Annual Meeting; May 31-June 4, 2019; Chicago.
Comments